Standardized Follow-up of Patients with Symptomatic Knee Osteoarthritis Treated with a Single Intra-articular Injection of a Combination of Cross-Linked Hyaluronic Acid and Mannitol.
OBJECTIVE
The objective of this study is to obtain pilot data from daily practice conditions of a viscosupplement made of a cross-linked high-molecular-weight hyaluronic acid (HA) combined with mannitol in patients with knee osteoarthritis (KOA).


METHODS
The data of 40 consecutive patients, 29 women and 11 men, who were prospectively followed up for 6 months, using a standardized procedure, were retrospectively analyzed. All patients have received a single intra-articular injection of HAnox-M-XL (4.4 mL), viscosupplement made of a cross-linked HA (16 mg/mL) + mannitol (35 mg/mL), in the target knee. The primary outcome was safety. The secondary end points included 3- and 6-month change in the WOMAC pain (0-50) and WOMAC total (0-240) and patient's global assessment (PGA). Patient's self-assessment of treatment efficacy (0-3) and analgesic consumption were obtained at months 3 and 6. An intent-to-treat analysis was performed.


RESULTS
Mean (SD) age was 60.7 (13.9) years, and mean BMI was 28.6 (5.0). Kellgren-Lawrence radiological grade was I/II and III/IV in 13 and 27 of the subjects, respectively. The average WOMAC pain and WOMAC total scores at baseline were 21.5 (9.8) and 89.9 (42.8), respectively. Thirty-nine patients completed the follow-up. HAnox-M-XL was well tolerated; two patients experienced knee pain after injection, which resolved within three days. No treatment-related severe adverse event was reported. Mean (SD) variations in WOMAC pain and WOMAC total scores were -8.2 (8.9) and -38.4 (35.6), respectively, at month 6 (P = 0.001). PGA decreased from 5.5 (2.0) to 3.0 (2.2) (P = 0.006). Efficacy was rated as good or very good in 76.9% of the cases. Most of the regular analgesics users decreased their consumption.


CONCLUSIONS
Treatment with one injection of 4.4 mL HAnox-M-XL is effective to alleviate KOA symptoms over six months, without safety concern. Controlled trials are needed to confirm these pilot data.
Department of Rheumatology, Hôpital Nord Franche-Comté, Belfort, France.
Thierry
T
Conrozier
Department of Rheumatology, Hôpital Nord Franche-Comté, Belfort, France.
Ana-Maria
AM
Bozgan
Department of Rheumatology, Hôpital Nord Franche-Comté, Belfort, France.
Marie
M
Bossert
Department of Rheumatology, Hôpital Nord Franche-Comté, Belfort, France.
Maxime
M
Sondag
Department of Rheumatology, Hôpital Nord Franche-Comté, Belfort, France.
Anne
A
Lohse-Walliser
Department of Rheumatology, Hôpital Nord Franche-Comté, Belfort, France.
Jean-Charles
JC
Balblanc
hyaluronic acid; intra-articular injection; knee osteoarthritis; mannitol; viscosupplementation
Clin Pharmacokinet. 2002;41(8):603-13
12102643
Ann Rheum Dis. 1957 Dec;16(4):494-502
13498604
Ann Rheum Dis. 2003 Dec;62(12):1145-55
14644851
Surg Technol Int. 2004;12:278-89
15455338
Osteoarthritis Cartilage. 2006 Dec;14(12):1237-47
16806998
Carbohydr Res. 2007 Jan 15;342(1):96-102
17123492
Osteoarthritis Cartilage. 2007 Dec;15(12):1424-36
17448701
Ann Rheum Dis. 2010 Jan;69(1):113-9
19304567
Semin Arthritis Rheum. 2009 Aug;39(1):1-9
19539353
Ann Rheum Dis. 2010 Aug;69(8):1453-8
20498210
BMC Musculoskelet Disord. 2011 Aug 24;12:195
21861935
J Orthop Res. 2012 May;30(5):679-85
22025307
J Biomed Mater Res B Appl Biomater. 2012 Feb;100(2):457-62
22102374
Pharmacology. 2012;89(1-2):18-21
22236612
Ann Rheum Dis. 2012 Sep;71(9):1454-60
22294639
Arthritis Care Res (Hoboken). 2012 Apr;64(4):465-74
22563589
Arthritis Care Res (Hoboken). 2012 Nov;64(11):1699-707
22674853
Arthritis Res Ther. 2012 Jun 21;14(3):R151
22721434
Osteoarthritis Cartilage. 2012 Nov;20(11):1336-46
22809835
Ann Intern Med. 2012 Aug 7;157(3):180-91
22868835
Age Ageing. 2013 Mar;42 Suppl 1:i1-57
23420266
J Orthop Res. 2013 Jun;31(6):901-7
23423846
Rev Esp Cir Ortop Traumatol. 2012 Jul-Aug;56(4):274-80
23594845
Drug Res (Stuttg). 2013 Sep;63(9):445-9
23599036
Osteoarthritis Cartilage. 2014 Mar;22(3):363-88
24462672
Inflamm Res. 2014 Aug;63(8):691-701
24858301
Semin Arthritis Rheum. 2014 Dec;44(3):253-63
24953861
Int J Immunopathol Pharmacol. 2014 Apr-Jun;27(2):245-52
25004836
Ann Intern Med. 2015 Jan 6;162(1):46-54
25560713
Arthroscopy. 2015 Oct;31(10):2036-45.e14
25998016
Patient Prefer Adherence. 2015 Jun 11;9:733-44
26089650
Semin Arthritis Rheum. 2015 Oct;45(2):140-9
26094903
Br J Sports Med. 2016 Jan;50(2):84-92
26729890
Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11
26806188
Springerplus. 2016 Feb 24;5:170
27026867
Rheumatol Ther. 2014 Dec;1(1):45-54
27747759
J Rheumatol. 1988 Dec;15(12):1833-40
3068365
J Rheumatol Suppl. 1993 Aug;39:3-9
8410881
Eur J Clin Chem Clin Biochem. 1997 May;35(5):355-63
9189739